Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

E. Kerem; M. W. Konstan; [No Value] et al; I. Bronsveld; X. Cystic Fibrosis Ataluren Study Group; S.M. Rowe

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

E. Kerem
, M. W. Konstan
, [No Value] et al
, I. Bronsveld
, X. Cystic Fibrosis Ataluren Study Group
, S.M. Rowe

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	539-547
Number of pages	9
Journal	The Lancet Respiratory Medicine
Volume	2
Issue number	7
Publication status	Published - 2014

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/24836205

Cite this

@article{9c0fe111f64146dab966af5b72d3e58a,

title = "Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.",

author = "E. Kerem and Konstan, \{M. W.\} and \{et al\}, \{[No Value]\} and I. Bronsveld and \{Cystic Fibrosis Ataluren Study Group\}, X. and S.M. Rowe",

year = "2014",

language = "English",

volume = "2",

pages = "539--547",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier Limited",

number = "7",

}

TY - JOUR

T1 - Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

AU - Kerem, E.

AU - Konstan, M. W.

AU - et al, [No Value]

AU - Bronsveld, I.

AU - Cystic Fibrosis Ataluren Study Group, X.

AU - Rowe, S.M.

PY - 2014

Y1 - 2014

M3 - Article

SN - 2213-2600

VL - 2

SP - 539

EP - 547

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 7

ER -